| abstract |
The object is to inhibit the phosphorylation activity of PKD and the transcription inhibition activity of AP2α with high efficiency and improve the efficiency of transcription of ABCA1 gene. Disclosed is an AP2 inhibitor comprising a doxazosin compound (e.g., doxazosin, a derivative thereof, or a (physiologically or pharmacologically acceptable) salt of doxazosin or the derivative). Preferably, the doxazosin compound is doxazosin mesilate or the like. The doxazosin compound can inhibit the phosphorylation activity of PKD and the transcription inhibition activity of AP2α with high efficiency, and can also promote the transcription of ABCA1 gene to thereby promote the production of an HDL. Thus, further disclosed are: a PKD inhibitor, an ABCA1 transcription promoter and an HDL production promoter, each comprising a doxazosin compound; and an ABCA1 transcription promoter and an HDL production promoter, each comprising the AP2 inhibitor or the PKD inhibitor. |